Key Inclusion Criteria:

          -  Histologically confirmed NSCLC that is at advanced stage. Advanced is defined as
             unresectable or metastatic disease. Patients must have exhausted all approved
             available therapies appropriate for the patient.

          -  Has available archival tumor tissue, unless discussed with the medical monitor.

          -  Willing to provide tumor tissue from newly obtained biopsy. Newly obtained biopsies at
             screening are required unless medically contra-indicated and discussed with the
             medical monitor. For patients in expansion cohorts, biopsies should be taken from
             tumor site which has not been irradiated previously and is not the only measurable
             target lesion.

          -  Previously documented presence of MET alterations: either MET-exon14 gene mutation
             and/or MET gene amplification, and/or elevated MET protein expression, as defined in
             the protocol.

        Key Exclusion Criteria:

          -  Has received treatment with an approved systemic therapy or has participated in any
             study of an investigational agent or investigational device within 2 weeks or 5
             half-lives of the prior treatment whichever is shorter with a minimum of 7 days from
             the first dose of study therapy

          -  Has not yet recovered (i.e. grade ≤1 or baseline) from any acute toxicities resulting
             from prior therapy except as described in the protocol

          -  Has received radiation therapy or major surgery within 14 days of first administration
             of study drug or has not recovered (i.e. grade ≤1 or baseline) from AEs, except for
             laboratory changes as described in the protocol and patients with grade ≤2 neuropathy

          -  For expansion cohorts only: prior treatment with MET-targeted biologic therapy
             (function-blocking antibodies or ADCs)

          -  For expansion cohorts only (except cohort 1A) prior treatment with any MET-targeted
             agent including small molecule tyrosine kinase inhibitors eg, crizotinib, capmatinib,
             tepotinib, as defined in the protocol

          -  Untreated or active primary brain tumor, CNS metastases, leptomeningeal disease or
             spinal cord compression as defined in the protocol

        Note: Other protocol defined Inclusion/Exclusion criteria apply.